U.S. markets closed
  • S&P 500

    4,594.62
    -106.84 (-2.27%)
     
  • Dow 30

    34,899.34
    -905.04 (-2.53%)
     
  • Nasdaq

    15,491.66
    -353.57 (-2.23%)
     
  • Russell 2000

    2,245.94
    -85.52 (-3.67%)
     
  • Crude Oil

    68.15
    -10.24 (-13.06%)
     
  • Gold

    1,785.50
    +1.20 (+0.07%)
     
  • Silver

    23.11
    -0.39 (-1.66%)
     
  • EUR/USD

    1.1320
    +0.0108 (+0.96%)
     
  • 10-Yr Bond

    1.4820
    -0.1630 (-9.91%)
     
  • GBP/USD

    1.3338
    +0.0018 (+0.14%)
     
  • USD/JPY

    113.3100
    -2.0290 (-1.76%)
     
  • BTC-USD

    54,507.35
    -3,434.62 (-5.93%)
     
  • CMC Crypto 200

    1,365.60
    -89.82 (-6.17%)
     
  • FTSE 100

    7,044.03
    -266.34 (-3.64%)
     
  • Nikkei 225

    28,751.62
    -747.66 (-2.53%)
     

Ligand Outlicenses BEPro Tech To Develop Oral COVID-19 Antivirals

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has signed a collaboration agreement with Double-Crane Pharmaceutical Co Ltd (CRDC).

  • The agreement grants CRDC exclusive Asia territorial rights to develop an oral COVID-19 antiviral using Ligand's BEPro technology.

  • Ligand will receive an upfront payment regarding the collaboration, and if the program advances, clinical and regulatory milestone payments, and tiered royalties on net sales.

  • CRDC will be responsible for all costs related to the program.

  • BEPro is a proprietary prodrug technology that is specifically applicable to nucleotides and nucleotide analogs to develop compounds with improved product profiles.

  • Ligand has generated preclinical pharmacokinetics data showing its oral BEPro-enabled COVID-19 antivirals to have a favorable blood concentration profile and generate lower levels of active nucleotide in the kidney a potential site for toxicity.

  • Price Action: LGND shares are up 1.05% at $132.78 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.